PT-141 (10mg) – PT10

PT-141 (10mg) — Research Peptide

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II, with modified C-terminal chemistry that alters its receptor selectivity profile. PT-141 received FDA approval in 2019 (as Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first melanocortin receptor agonist to receive regulatory approval for a CNS-mediated sexual function indication, providing a substantial clinical research foundation for investigators.

Melanocortin Receptor Selectivity

PT-141 is a non-selective melanocortin agonist with activity at MC1R, MC3R, and MC4R. Its primary researched mechanism for sexual function operates through MC4R activation in hypothalamic circuits — specifically the medial preoptic area (MPOA) and paraventricular nucleus (PVN), which govern sexual motivation and arousal through downstream dopaminergic signalling. This central mechanism distinguishes it from PDE5 inhibitors (sildenafil, tadalafil), which operate through peripheral vascular mechanisms.

Phase 2 and 3 clinical data from the FDA approval programme documented statistically significant improvements in sexual desire and distress scores in HSDD, with the most common adverse effects being nausea, flushing, and transient blood pressure elevation — consistent with its melanocortin receptor activity profile.

Product Specifications

• Peptide: PT-141 (Bremelanotide)
• Dose: 10mg per vial
• Format: Lyophilised powder, bulk box of 10 vials
• Purity: ≥98% Janoshik HPLC verified
• Storage: -20°C. 24-month stability.

For laboratory research use only. Not for human therapeutic use outside approved indications.